Divi's Labs Reports 65% Jump in Q1 Profit as Custom Synthesis Drives Growth
The Indian pharmaceutical manufacturer posted consolidated profit after tax of INR 902 crores, benefiting from its integrated manufacturing model and expanding custom synthesis portfolio.
Strong Revenue and Profit Growth
Divi's Laboratories Limited reported consolidated total income of INR 3,144 crores for the first quarter of fiscal year 2027, compared to INR 2,529 crores in the corresponding quarter of the previous year (earnings call, 2026-08-01). Profit after tax increased 65% to INR 902 crores from INR 545 crores year-over-year.
On a stand-alone basis, the company recorded total income of INR 3,037 crores, representing 10% growth on a constant currency basis. Profit before tax rose to INR 1,165 crores from INR 747 crores in the prior-year period (earnings call, 2026-08-01).
Custom Synthesis Assumes Larger Role
The business mix for the quarter reflected a significant shift, with custom synthesis contributing 60% of revenue compared to 40% from generics (earnings call, 2026-08-01). Dr. Kiran S. Divi, Whole-Time Director and CEO, indicated that "3 major CapEx programs are nearing completion and validations are going on," with projects progressing across clinical development, validation, and commercial supply preparations (earnings call, 2026-08-01).
The company is supporting customer programs across "multiple therapeutic areas and stages of development" with manufacturing activities aligned to regulatory and filing requirements (earnings call, 2026-08-01).
Supply Chain Resilience Amid Challenges
Ms. Nilima Prasad Divi, Whole-Time Director, Commercial, acknowledged that "the external operating environment remained challenging during the quarter, particularly across global trade routes and sourcing channels linked to West Asia" (earnings call, 2026-08-01). While raw material availability remained largely stable, solvent costs stayed elevated for a significant portion of the period.
The company maintained strategic inventory buffers and continued diversifying its global supplier base to mitigate supply disruption risks. Global logistics conditions remained challenging, with elevated freight rates and container availability requiring "careful planning and coordination" (earnings call, 2026-08-01).
Manufacturing and Strategic Investments
Net material consumption for the quarter was 31.2% of revenue from operations on a stand-alone basis, "reflecting the continued benefits of our integrated manufacturing model and product mix" (earnings call, 2026-08-01). Unit 3 continues to support the company's backward integration strategy through pre-chemistry operations.
The company capitalized assets amounting to INR 451 crores during the quarter, while capital work in progress stood at INR 2,034 crores as of June 30, 2026 (earnings call, 2026-08-01).
Geographic Mix and Nutraceuticals
Exports accounted for approximately 90% of stand-alone revenue, with Europe and North America representing 75% of exports (earnings call, 2026-08-01). The global nutraceutical business, marking its 20th year, reported revenue of INR 298 crores compared to INR 250 crores in the corresponding quarter last year.
Dr. Divi noted that what "began with just 2 products has grown into a portfolio of over 100 offerings across human health, animal health and battery supplements" (earnings call, 2026-08-01).
As of quarter-end, cash and cash equivalents stood at INR 3,611 crores, trade receivables were INR 3,056 crores, and inventory stood at INR 4,413 crores (earnings call, 2026-08-01).
This article was generated by MarginX from the earnings call on 2026-08-01. It is not investment advice.